Polycystic kidney disease interventions: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 15: | Line 15: | ||
*[[Peritoneal dialysis]] may have a survival benefit over [[hemodialysis]]<ref name="pmid11924752">{{cite journal |vauthors=Abbott KC, Agodoa LY |title=Polycystic kidney disease at end-stage renal disease in the United States: patient characteristics and survival |journal=Clin. Nephrol. |volume=57 |issue=3 |pages=208–14 |date=March 2002 |pmid=11924752 |doi= |url=}}</ref> | *[[Peritoneal dialysis]] may have a survival benefit over [[hemodialysis]]<ref name="pmid11924752">{{cite journal |vauthors=Abbott KC, Agodoa LY |title=Polycystic kidney disease at end-stage renal disease in the United States: patient characteristics and survival |journal=Clin. Nephrol. |volume=57 |issue=3 |pages=208–14 |date=March 2002 |pmid=11924752 |doi= |url=}}</ref> | ||
*[[Hemodialysis]] is the preferred modality for [[Renal replacement therapy|renal replacement]] in patients with polycystic kidney disease<ref name="pmid9044324">{{cite journal |vauthors=Pirson Y, Christophe JL, Goffin E |title=Outcome of renal replacement therapy in autosomal dominant polycystic kidney disease |journal=Nephrol. Dial. Transplant. |volume=11 Suppl 6 |issue= |pages=24–8 |date=1996 |pmid=9044324 |doi= |url=}}</ref> | *[[Hemodialysis]] is the preferred modality for [[Renal replacement therapy|renal replacement]] in patients with polycystic kidney disease<ref name="pmid9044324">{{cite journal |vauthors=Pirson Y, Christophe JL, Goffin E |title=Outcome of renal replacement therapy in autosomal dominant polycystic kidney disease |journal=Nephrol. Dial. Transplant. |volume=11 Suppl 6 |issue= |pages=24–8 |date=1996 |pmid=9044324 |doi= |url=}}</ref> | ||
==Contraindications== | ==Contraindications== | ||
Revision as of 15:08, 8 June 2018
|
Polycystic kidney disease Microchapters |
|
Differentiating Polycystic kidney disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Polycystic kidney disease interventions On the Web |
|
American Roentgen Ray Society Images of Polycystic kidney disease interventions |
|
Risk calculators and risk factors for Polycystic kidney disease interventions |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]
Overview
Dialysis is not the first-line treatment option for patients with polycystic kidney disease. Dialysis is usually reserved for patients with either end stage renal disease (ESRD) or renal failure.
Indications
Dialysis is not the first-line treatment option for patients with polycystic kidney disease. Dialysis is usually reserved for patients with either:[1]
Dialysis
- Dialysis is the mainstay of treatment for ESRD and renal failure in patients with polycystic kidney disease[2]
- Peritoneal dialysis may have a survival benefit over hemodialysis[3]
- Hemodialysis is the preferred modality for renal replacement in patients with polycystic kidney disease[2]
Contraindications
- Peritoneal dialysis is not preferred in patients with PKD, because of the lack of ability to acoomodate large volume of peritoneal fluid[4]
- Peritoneal dialysis is also avoided in patients with aortic aneurysms
- Anticoagulants required for hemodialysis should be used with caution due to pre existing hematuria
References
- ↑ Grantham JJ (October 2008). "Clinical practice. Autosomal dominant polycystic kidney disease". N. Engl. J. Med. 359 (14): 1477–85. doi:10.1056/NEJMcp0804458. PMID 18832246.
- ↑ 2.0 2.1 Pirson Y, Christophe JL, Goffin E (1996). "Outcome of renal replacement therapy in autosomal dominant polycystic kidney disease". Nephrol. Dial. Transplant. 11 Suppl 6: 24–8. PMID 9044324.
- ↑ Abbott KC, Agodoa LY (March 2002). "Polycystic kidney disease at end-stage renal disease in the United States: patient characteristics and survival". Clin. Nephrol. 57 (3): 208–14. PMID 11924752.
- ↑ Lederman ED, McCoy G, Conti DJ, Lee EC (February 2000). "Diverticulitis and polycystic kidney disease". Am Surg. 66 (2): 200–3. PMID 10695753.